Aerpio Pharmaceuticals Inc. (ARPO)’s Financial Results Comparing With Zymeworks Inc. (NYSE:ZYME)

Both Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Zymeworks Inc. (NYSE:ZYME) are Biotechnology companies, competing one another. We will compare their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerpio Pharmaceuticals Inc. 1 1.56 N/A -0.36 0.00
Zymeworks Inc. 21 20.95 N/A -0.94 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of Aerpio Pharmaceuticals Inc. and Zymeworks Inc.


Table 2 represents Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Zymeworks Inc. (NYSE:ZYME)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aerpio Pharmaceuticals Inc. 0.00% -20.5% -17.7%
Zymeworks Inc. 0.00% -16.4% -13.1%


The current Quick Ratio of Aerpio Pharmaceuticals Inc. is 13.8 while its Current Ratio is 13.8. Meanwhile, Zymeworks Inc. has a Current Ratio of 6.8 while its Quick Ratio is 6.8. Aerpio Pharmaceuticals Inc. is better positioned to pay off its short-term and long-term debts than Zymeworks Inc.

Analyst Recommendations

Aerpio Pharmaceuticals Inc. and Zymeworks Inc. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aerpio Pharmaceuticals Inc. 0 0 0 0.00
Zymeworks Inc. 0 1 3 2.75

Competitively the consensus price target of Zymeworks Inc. is $37.75, which is potential 39.04% upside.

Insider & Institutional Ownership

Roughly 23.4% of Aerpio Pharmaceuticals Inc. shares are owned by institutional investors while 49.2% of Zymeworks Inc. are owned by institutional investors. Aerpio Pharmaceuticals Inc.’s share owned by insiders are 1.1%. Comparatively, Zymeworks Inc. has 5.7% of it’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%
Zymeworks Inc. -5.97% -0.57% 21.67% 47.61% 87.14% 55.65%

For the past year Aerpio Pharmaceuticals Inc. had bearish trend while Zymeworks Inc. had bullish trend.


Zymeworks Inc. beats Aerpio Pharmaceuticals Inc. on 6 of the 8 factors.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companyÂ’s lead product candidate include ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast, gastric, and ovarian cancers. It is also developing ZW33, a bispecific anti-human epidermal growth factor receptor 2 antibody-drug conjugate that is in preclinical development stage for the treatment of breast and ovarian cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Celgene Corporation and Celgene Alpine Investment Co. LLC, GlaxoSmithKline Intellectual Property Development Limited, and Daiichi Sankyo Co., Ltd. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.